

**UNITED STATES BANKRUPTCY COURT
FOR THE MIDDLE DISTRICT OF PENNSYLVANIA**

IN RE:	)	
	)	Chapter 11
	)	
UNITED GILSONITE	)	Case No. 5:11-bk-02032 (RNO)
LABORATORIES,	)	
A PENNSYLVANIA CORPORATION,¹	)	
	)	
	)	
REORGANIZED DEBTOR.	)	
	)	

**ANNUAL REPORT, FINANCIAL STATEMENTS AND
RESULTS OF OPERATIONS OF THE UNITED GILSONITE LABORATORIES
ASBESTOS PERSONAL INJURY TRUST FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2025**

Alan B. Rich, the Trustee of the United Gilsonite Laboratories Asbestos Personal Injury Trust (the “UGL Trust”), created pursuant to the Modified First Amended Plan of Reorganization of United Gilsonite Laboratories Under Chapter 11 of the Bankruptcy Code dated as of September 30, 2014 (the “Plan”),² submits this Annual Report, Financial Statements and Results of Operations of the United Gilsonite Laboratories Asbestos Personal Injury Trust for the Fiscal Year Ended December 31, 2025.³

¹ The last four digits of the Debtor’s federal tax identification number are 7530.

² Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Plan.

³ Pursuant to the Final Decree and Order Closing the Chapter 11 Case of United Gilsonite Laboratories (Docket No. 2402), the Clerk of the Court shall not refuse to accept for filing any report submitted by the Trustee for the UGL Trust on the grounds that the Chapter 11 Case is closed.

I. General

On March 23, 2011, United Gilsonite Laboratories filed a voluntary petition for relief under Chapter 11, Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Middle District of Pennsylvania (the “Bankruptcy Court”). On December 8, 2014, the Bankruptcy Court entered the Findings of Fact, Conclusions of Law, and Order Approving Exit Facility and Confirming the Modified First Amended Plan of Reorganization of United Gilsonite Laboratories Under Chapter 11 of the Bankruptcy Code (the “Confirmation Order”), which confirmed the Plan of the above-referenced debtor. On December 8, 2014, the United States District Court for the Middle District of Pennsylvania entered its Order Under 11 U.S.C. § 524(g)(3)(A) Affirming Bankruptcy Court’s Confirmation of Chapter 11 Reorganization Plan and Issuance of Channeling Injunction affirming the Confirmation Order.

Pursuant to the Plan, the UGL Trust was established on December 31, 2014 (the “Effective Date”).

Pursuant to the Plan, Beth Gori, Ethan Early, Joseph Belluck, Jonathan Ruckdeschel, and John P. Comerford are the members of the Trust Advisory Committee (“TAC”) and James L. Patton is the Future Claimants’ Representative (“FCR”).

II. Trust Claims

Section 2.2(b) of the United Gilsonite Laboratories Asbestos Personal Injury Trust Agreement (the “Trust Agreement”) requires the Trustee to account to the Bankruptcy

Court and file an annual report containing financial statements of the UGL Trust and a summary of the number and type of claims disposed of by the UGL Trust during the period covered by the financial statements.

The UGL Trust through its claims processing facility—Claims Processing Facility, Inc.—began accepting Trust Claims on December 17, 2015. From inception of the UGL Trust through the period ending December 31, 2025, 12,195 Trust Claims have been submitted to the UGL Trust, including 500 Trust Claims submitted in 2025, as follows:

Disease Level	Claims submitted from Trust's inception through 12/31/25	Claims submitted in 2025
Mesothelioma (Level VIII)	3,134	189
Lung Cancer 1 (Level VII)	5,556	192
Lung Cancer 2 (Level VI)	2,189	83
Other Cancer (Level V)	480	6
Severe Asbestosis (Level IV)	397	19
Asbestosis/Pleural Disease (Level III)	153	4
Asbestosis/Pleural Disease (Level II)	286	7
Other Asbestos Disease (Level I)	0	0
Total:	12,195	500

Of the 12,195 Trust Claims submitted to the UGL Trust, the UGL Trust has not approved 10,741 claims, including rejected claims, claims with uncured deficiencies, and

withdrawn and deferred claims. As of December 31, 2025, the UGL Trust has paid a total of 1,320 Trust Claims. In 2025, the Trust liquidated and paid 136 Trust Claims, totaling \$1,012,754, after application of the Payment Percentage.⁴

Under Section 4.3 of the Trust Agreement the Trust reports payments for Trust Expenses. The Trust's operating expenses are listed in the Special Purpose Financial Statements of Changes in Net Claimants' Equity. *See* Exhibit A attached hereto at page 5.

III. Compensation and Expenses of the Trustee, TAC and FCR.

Under Section 5.5(d) of the Trust Agreement, the UGL Trust reports to the Bankruptcy Court the amount of compensation and expenses paid to the Trustee and the Delaware Trustee. The Trustee and the Delaware Trustee received compensation and reimbursement for out-of-pocket expenses during the period from January 1, 2025 through December 31, 2025 as set forth in the Special-Purpose Financial Statements of Changes in Net Claimants' Equity.

Under Section 6.6 of the Trust Agreement, the Trustee reports to the Bankruptcy Court the amount of compensation and expenses paid to the TAC and its counsel. The TAC and its counsel received compensation and reimbursement for out-of-pocket expenses during the period from January 1, 2025 through December 31, 2025 as set forth in the Special-Purpose Financial Statements of Changes in Net Claimants' Equity.

Under Section 7.6 of the Trust Agreement, the Trustee reports to the Bankruptcy Court the amount of compensation and expenses paid to the Future Claimants' Representative (the "FCR") and his counsel. The FCR and his counsel received compensation and reimbursement

⁴ Trust Claims paid by the Trust in 2025 are reported herein on a cash basis.

for out-of-pocket expenses during the period from January 1, 2025 through December 31, 2025 as set forth in the Special-Purpose Financial Statements of Changes in Net Claimants' Equity.

IV. Financial Statements

A copy of the UGL Trust's audited special-purpose financial statements for the year ended December 31, 2025, including Special-Purpose Financial Statements of Net Claimants' Equity and Special-Purpose Financial Statements of Changes in Net Claimants' Equity, is attached hereto as Exhibit "A".

Respectfully submitted,

Dated: April 21, 2026

**STUTZMAN, BROMBERG, ESSERMAN &
PLIFKA, A Professional Corporation**

By: /s/ Sander L. Esserman

Sander L. Esserman (Tex. Bar No. 06671500)
Andrea L. Ducayet (Tex. Bar No. 24032790)
2323 Bryan Street, Suite 2200
Dallas, TX 75201
Telephone: 214-969-4900
Facsimile: 214-969-4999
esserman@sbep-law.com
ducayet@sbep-law.com

**COUNSEL FOR THE UNITED
GILSONITE LABORATORIES ASBESTOS
PERSONAL INJURY TRUST**

EXHIBIT A

**United Gilsonite Laboratories Asbestos
Personal Injury Trust**

**Special-Purpose Financial Statements
and Independent Auditor's Report**

Years Ended December 31, 2025 and 2024



United Gilsonite Laboratories Asbestos Personal Injury Trust

Index

	PAGE
Independent Auditor's Report	2
Financial Statements	
Special-Purpose Statements of Net Claimants' Equity	4
Special-Purpose Statements of Changes in Net Claimants' Equity	5
Notes to Special-Purpose Financial Statements	6

Independent Auditor's Report

To the Trustee of
United Gilsonite Laboratories Asbestos Personal Injury Trust

Opinion

We have audited the accompanying special-purpose financial statements of the United Gilsonite Laboratories Asbestos Personal Injury Trust (the "Trust"), which comprise the special-purpose statements of net claimants' equity as of December 31, 2025 and 2024, and the related special-purpose statements of changes in net claimants' equity for the years then ended, and the related notes to the special-purpose financial statements (collectively, the "Financial Statements").

In our opinion, the Financial Statements referred to above present fairly, in all material respects, the net claimants' equity of the Trust as of December 31, 2025 and 2024 and the changes in net claimants' equity for the years then ended in accordance with the basis of accounting described in Note 2 to the Financial Statements.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Trust and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide our audit opinion.

Basis of Accounting

We draw attention to Note 2 of the Financial Statements, which describes the basis of accounting. The Financial Statements are prepared on a special-purpose basis of accounting which is a basis of accounting other than accounting principles generally accepted in the United States of America. The special-purpose basis of accounting has been adopted by the Trustee to communicate the amount of net claimants' equity presently available to fund current and future claimants. As a result, the Financial Statements may not be suitable for another purpose. Our opinion is not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these Financial Statements in accordance with the special-purpose basis of accounting; this includes determining that the special-purpose basis of accounting is an acceptable basis for the preparation of the Financial Statements in these circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the Financial Statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the Financial Statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the Financial Statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Trust's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Restriction on Use

This report is intended solely for the information and use of the management of the Trust, the Trustee, the beneficiaries of the Trust and the United States Bankruptcy Court for the Middle District of Pennsylvania and is not intended to be and should not be used by anyone other than these specified parties. Upon filing with the United States Bankruptcy Court for the Middle District of Pennsylvania, the report is a matter of public record, which public filing does not expand the list of specified users.



Frisco, Texas
April 20, 2026

United Gilsonite Laboratories Asbestos Personal Injury Trust

**Special-Purpose Financial Statements of Net Claimants' Equity
December 31, 2025 and 2024**

	<u>Assets</u>	
	2025	2024
Cash and cash equivalents		
Unrestricted	\$ 373,321	\$ 430,262
Restricted	59,550	47,700
Investments in marketable securities and certificate of deposit at fair value	12,697,459	13,076,311
Accrued interest and dividend income	113,632	135,768
Purchased interest	-	3,083
Prepaid expenses	45,069	43,335
Total assets	<u>\$ 13,289,031</u>	<u>\$ 13,736,459</u>
<u>Liabilities and Net Claimants' Equity</u>		
Accrued expenses	\$ 59,929	\$ 76,705
Accrued payments to claimants	289,210	194,563
Claims processing deposits	59,550	47,700
Total liabilities	<u>408,689</u>	<u>318,968</u>
Net claimants' equity	<u>\$ 12,880,342</u>	<u>\$ 13,417,491</u>

See Notes to Special-Purpose Financial Statements.

United Gilsonite Laboratories Asbestos Personal Injury Trust

**Special-Purpose Financial Statements of Changes in Net Claimants' Equity
December 31, 2025 and 2024**

	2025	2024
Additions		
Interest and dividend income - marketable securities	\$ 782,999	\$ 822,495
Net gain on investments in marketable securities, net of management fees, custody fees and bond amortization	256,319	-
Filing fees collected on withdrawn claims and other	12,100	6,100
Total additions	1,051,418	828,595
Deductions		
Payments to Claimants	1,107,400	852,052
Net loss on investments in marketable securities, net of management fees, custody fees and bond amortization	-	224,930
Legal fees	157,426	147,102
Trustee fees and expenses	84,168	87,810
Accounting fees	55,659	70,878
Claims processing fees	38,000	19,775
Consulting fees	30,500	19,877
Trustee annual fee	25,000	25,000
Financial consulting fees	20,000	20,000
Future claimants' representative fees and expenses	19,638	50,975
Insurance expense	18,441	18,445
Audit fees	14,399	20,534
Trust advisory committee member fees and expenses	11,528	41,495
Delaware Trustee fees and expenses	3,000	3,000
Miscellaneous expenses	2,108	1,531
Foreign taxes paid	1,300	2,197
Total deductions	1,588,567	1,605,601
Net decrease in net claimants' equity	(537,149)	(777,006)
Net claimants' equity, beginning of year	13,417,491	14,194,497
Net claimants' equity, end of year	\$ 12,880,342	\$ 13,417,491

See Notes to Special-Purpose Financial Statements.

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

Note 1 - Description of Trust

The United Gilsonite Laboratories Asbestos Personal Injury Trust (the "Trust") was established in accordance with the modified First Amended Plan of Reorganization (the "Plan"), under Chapter 11 of the United States Bankruptcy Code, of United Gilsonite Laboratories ("UGL"). The purpose of the Trust is:

- To assume the liability for all Trust Claims asserted against the Asbestos Protected Parties;
- To preserve, hold, manage, and maximize the Trust assets for use in paying and otherwise satisfying Trust Claims and paying Trust Expenses;
- To direct the processing, liquidation and payment of Trust Claims in accordance with the Trust Distribution Procedures ("TDP"); and
- To otherwise comply in all respects with the requirements for a trust set forth in Section 524(g)(2)(B) of the Bankruptcy Code, all in accordance with the Plan and the Trust Agreement.

The Trust was established on December 31, 2014, the Effective Date of the Plan ("Effective Date"), and is a Qualified Settlement Fund under Internal Revenue Code (the "Code") Section 468B for holders of asbestos personal injury claims ("Qualified Settlement Fund"). The Trust operates as the United Gilsonite Laboratories Asbestos Personal Injury Trust.

Pursuant to the Plan, UGL paid \$11,000,000 of company cash and \$6,036,880 of shareholder cash, for a total cash contribution of \$17,036,880, at formation of the Trust. In addition, the Trust received from UGL a Promissory Note receivable in the amount of \$7,250,000 and a Shareholder Promissory Note receivable in the amount of \$375,000. The Promissory Note receivable was paid in full on May 5, 2017. The Shareholder Promissory Note receivable was paid in full on January 2, 2015. Also, UGL transferred its rights under insurance policies to the Trust in the amount of \$10,355,835. In December 2019, The Trust received \$300,000 from UGL, representing the original and final balance in the litigation reserve fund.

The Trust is governed by a Trust Agreement and TDP that establish the framework and criteria for allowance and payment of Claims by the Trust. The Trust Agreement and TDP were approved by the United States District Court as part of the Plan. There are eight disease levels specified in the TDP. Each claimant who meets the medical and exposure requirements of the TDP for a particular disease level may apply for expedited review and a specified payment amount. Claimants for certain disease levels also have an alternative, under the TDP, to submit additional documentation and request a more expansive review of their Claim ("Individual Review Process") in which these case claims may be paid within a range of amounts.

The Trust's assets consist primarily of cash and cash equivalents, investments in marketable securities and a certificate of deposit, which, with the earnings (or losses) on such investments, are intended to be totally consumed by the allowance and payment of claims and operation of the Trust. The percentage amount of each allowed claim that will actually be paid will be determined by projections of total allowed Claims and operational expense of the Trust, on the one hand, and total assets and net earnings (or losses), on the other. The Trust began accepting claims in paper format on December 17, 2015, and online using the e-File system on March 17, 2016. The Trust began paying claims in June 2016. The initial payment percentage was set at 11% and is subject to periodic review and adjustment. Pursuant to TDP Section 4.3, the Trustee reconsidered the payment percentage. Effective April 11, 2024, the Trust, with the consent of the Trust Advisory Committee and the Future Claimants' Representative, set the Payment Percentage at 3.35%. The Trustee is a fiduciary to the beneficiaries of the Trust and is responsible for administering the Trust and the Trust's assets in accordance with the Trust Agreement and the Plan.

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

Termination

The Trust Agreement (Section 8.2) provides that the Trust shall automatically dissolve on the date (the "Dissolution Date") ninety (90) days after the first to occur of the following events:

- The date on which the Trustee decides to dissolve the Trust because (A) the Trustee deems it unlikely that any new Trust Claims will be filed against the Trust, (B) all Trust Claims duly filed with the Trust have been liquidated and, to the extent possible based upon the funds available to the Trust through the Plan, paid to the extent provided in the Trust Agreement and TDP, or have been disallowed by a final, non-appealable order, and (C) twelve (12) consecutive months have elapsed during which no new Trust Claim has been filed with the Trust;
- If the Trustee has procured and has in place irrevocable insurance policies and has established claims handling agreements and other necessary arrangements with suitable third parties adequate to discharge all expected remaining obligations and expenses of the Trust in a manner consistent with the Trust Agreement and the TDP, the date on which the Bankruptcy Court enters an order approving such insurance and other arrangements and such order becomes a final order; or
- To the extent that a rule against perpetuities shall be deemed applicable to the Trust, that date which is twenty-one (21) years less ninety-one (91) days after the death of the last survivor of all the descendants of the late Joseph P. Kennedy, Sr., father of the late President John F. Kennedy, living on the date hereof.

On the Dissolution Date or as soon as reasonably practicable, after the wind-up of the Trust's affairs by the Trustee and payment of all the Trust's liabilities have been provided for as required by applicable law, all remaining assets shall be applied to such charitable purposes, if practicable, which shall be related to the treatment of, research on, or the relief of individuals suffering from asbestos related disorders and such charitable organizations should not have any relationship with UGL.

Following the dissolution and distribution of the assets of the Trust, the Trust shall terminate and the Trustee shall execute and file a Certificate of Cancellation.

Note 2 - Summary of Significant Accounting Policies

Basis of accounting

The Trust's special-purpose financial statements ("Financial Statements") are prepared using special-purpose accounting methods that differ from accounting principles generally accepted in the United States of America ("GAAP"). The special-purpose accounting methods are being used to better communicate the equity available to satisfy current and future claims. Since the

accompanying Financial Statements and transactions are not based upon GAAP, accounting treatment by other parties for these same transactions may differ as to timing and amount.

These special-purpose accounting methods and the differences from GAAP are summarized as follows:

- The Financial Statements are prepared using the accrual basis of accounting, except as otherwise described herein.
- The statement of net claimants' equity is not classified, resulting in no separation between current and noncurrent assets.

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

- These Financial Statements do not include a statement of cash flows.
- Cash and cash equivalents are recorded at cost with accrued interest shown separately.
- The funding received from UGL and insurance settlements has been recorded directly to net claimants' equity. These funds do not represent taxable income to the Trust. Payments to Claimants are reported as deductions from net claimants' equity and do not represent tax-deductible expenses of the Trust.
- The liability for accrued payments to claimants reflected in the statements of net claimants' equity represents unpaid outstanding and accepted offers. No liability is recorded for future claims filings and filed claims on which no offer has been made. Net claimants equity represents funding available to pay present and future claims on which no liability has been recorded.
- The Trust's investments in marketable debt securities are considered as available for sale. The unrealized holdings gains (losses) on these investments are included in net gain or loss on investments in marketable securities, net of management fees, custody fees and bond amortization on the accompanying statement of changes in net claimants' equity. Under GAAP, the unrealized holding gains (losses) on available for sale investments would be included as a component of net claimants' equity reported as accumulated other comprehensive income (loss).

Use of estimates

The preparation of Financial Statements in conformity with the basis of accounting described above, requires the Trust to make estimates and assumptions that affect the reported amounts of certain assets and liabilities and the disclosure of contingent assets and liabilities at the date of the Financial Statements as well as the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include fair value of investments and the provision for income taxes. Actual results could differ from those estimates.

Financial instruments

The Trust's financial instruments are cash and cash equivalents, accrued interest and dividend income, investments in marketable securities, a certificate of deposit, and accrued expenses. The carrying amount of cash and cash equivalents, accrued interest and dividend income and accrued expenses approximate their fair values based on their short-term nature. The carrying amount of investments in marketable securities and certificate of deposit is based on fair value.

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

Cash and cash equivalents

The Trust considers all highly liquid debt instruments purchased with an original maturity value of three months or less to be cash equivalents. Unrestricted cash and cash equivalents at December 31, 2025 and 2024, are as follows:

	2025	2024
Money market funds		
Fidelity government fund	\$ 116,888	\$ 189,044
Vanguard prime fund	72,578	69,589
Texas Capital Bank	163,513	-
MapleMark Bank	-	161,712
Filing fee account	20,342	9,917
Total	<u>\$ 373,321</u>	<u>\$ 430,262</u>

At December 31, 2025 and 2024, restricted cash represents filing fees received from claimants, which will be refunded if the claim is accepted and retained by the Trust if the claim does not qualify for payment.

Concentrations of credit risk

Financial instruments, which potentially subject the Trust to concentrations of credit risk, consist primarily of cash and cash equivalents, investments in marketable securities, and a certificate of deposit. The Trust maintained a portion of its cash and cash equivalents in accounts that are not federally insured but considers them to be of high credit quality. The Trust has not experienced any losses in such accounts, and it does not believe it is exposed to any significant credit risk.

The Trust's investments are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with investments, it is at least reasonably possible that significant changes in risks in the near term may materially affect the amounts reported in the Financial Statements. However, the Trust has a formal investment policy of placing investments in high-quality financial institutions.

Investments in marketable securities and related income (loss)

Investments in marketable securities are reported at fair value in the special-purpose statements of net claimants' equity and changes in the fair value of investments, as well as unrealized and realized gains and losses are included in net gain or loss on investments in marketable securities, net of management fees, custody fees and bond amortization reported in the special-purpose statements of changes in net claimants' equity. Purchases and sales of marketable securities are recorded on the trade date. Realized gains and losses on disposals of investments are determined by the specific identification method. Interest and dividend income are recognized on the accrual basis.

Investments considered to be permanently impaired in value are written down to their estimated net realizable value and the write down is recorded as a realized loss on investments. Unrealized losses that are other-than-temporary based upon management's estimates using quantitative and qualitative criteria are recognized as realized investment losses. Actual results could differ from those estimates.

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

Claims processing deposits

Claims processing deposits represent filing fees collected for each unliquidated claim, which will be refunded by the Trust if the claim is paid.

Net claimants' equity

The Trust, under the adopted special-purpose accounting convention, does not record the liability for future claims expected to be filed over the life of the Trust. The net claimants' equity is available for (i) the payments of allowed asbestos-related claims and (ii) operational expenses of the Trust.

Income taxes

Deferred tax assets and liabilities are recorded based on temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is likely that the deferred tax assets may not be realized. In the opinion of management, the Trust is not subject to state income taxes and therefore, the Financial Statements do not include any provision or liability for state income taxes. Funds received by the Trust from UGL and from insurance settlements and disbursements paid to settle asbestos claims are not taxable or deductible by the Trust.

The Trustee's estimate of the potential outcome of any uncertain tax issues is subject to management's assessment of relevant risks, facts, and circumstances existing at that time. The Trust uses a more likely than not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. To the extent that the Trustees' assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. The Trust reports tax-related interest and penalties as a component of income tax expense and operating expenses, respectively. The Trust has no unrecognized tax benefits.

Subsequent events

The Trust has evaluated events and transactions subsequent to the date of the Financial Statements for matters requiring recognition or disclosure in the Financial Statements. The accompanying Financial Statements consider events through April 20, 2026, the date on which the Financial Statements were available to be issued.

Note 3 - Investments in Marketable Securities and Certificate of Deposit

The Trust measures its investments, at fair value, according to a hierarchy of valuation techniques. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies an investment for each level:

Level I - Quoted prices are available in active markets for identical investments as of the reporting date.

Level II - Pricing inputs are other than quoted market prices included in Level I, however are observable indirectly for the investment

Level III - Pricing inputs are unobservable for the investment and includes situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation. The Trust does not carry any Level III investments.

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

The following section describes the valuation methodologies the Trust uses to measure its financial assets at fair value.:

Mutual funds: Value at the closing price reported on the active market on which the individual securities are traded.

Certificates of deposit and municipal bonds: Value using the documented trade price if trading in an active market. Otherwise, value using a metrics system provided by the pricing vendors.

The valuations of the Trust's investments in marketable securities by the above fair value hierarchy levels and the corresponding cost of the investments as of December 31, 2025, are as follows:

December 31, 2025				
	Level	Fair Value	Cost	Unrealized gains (losses), net
Mutual funds - equity funds	I	\$ 4,249,443	\$ 3,179,084	\$ 1,070,359
Municipal bonds	II	8,448,016	8,393,929	54,087
Total		<u>\$ 12,697,459</u>	<u>\$ 11,573,013</u>	<u>\$ 1,124,446</u>

The valuations of the Trust's investments in marketable securities and certificate of deposit by the above fair value hierarchy levels and the corresponding cost of the investments as of December 31, 2024, are as follows:

December 31, 2024				
	Level	Fair Value	Cost	Unrealized gains, net
Certificate of deposit	II	\$ 294,566	\$ 294,566	\$ -
Mutual funds - equity funds	I	4,221,899	3,135,694	1,086,205
Municipal bonds	II	8,559,846	8,666,507	(106,661)
Total		<u>\$ 13,076,311</u>	<u>\$ 12,096,767</u>	<u>\$ 979,544</u>

Maturities of the Trust's debt securities at December 31, 2025 are as follows:

	Level	Fair Value	Cost	Unrealized gains (Losses), Net
Due in one year or less	II	\$ 939,137	\$ 939,053	\$ 84
Due after one year through five years	II	1,012,637	1,020,737	(8,100)
Due after five years through ten years	II	2,219,576	2,209,048	10,528
Due after ten years through twenty years	II	2,419,281	2,379,485	39,796
Due after twenty years	II	1,857,385	1,845,606	11,779
Total		<u>\$ 8,448,016</u>	<u>\$ 8,393,929</u>	<u>\$ 54,087</u>

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

The net gain (loss) on investments in marketable securities is calculated as follows for the years ended December 31, 2025 and 2024:

	2025	2024
Realized gains	\$ 221,706	\$ 141,225
Unrealized gains (losses), net	144,901	(221,234)
Management fees	(12,442)	(13,340)
Custody fees	(5,096)	(5,851)
Bond amortization	(92,750)	(125,730)
Net gain (loss) on investments	<u>\$ 256,319</u>	<u>\$ (224,930)</u>

Note 4 - Taxation

The Trust reports its income to the Internal Revenue Service as a designated settlement fund which is taxed at the highest rate applicable to trusts under Section I(e) of the Code, which was 37% for the years ending December 31, 2025 and 2024.

For net operating losses ("NOLs") created in years beginning after December 31, 2017, the carryforward of NOLs will be limited to a reduction of 80% of modified taxable income without expiration. NOLs prior to January 1, 2018 will carry forward 20 years, and there is no limitation in the reduction of modified taxable income.

The Trust's federal income tax expense (benefit) is calculated as follows:

	Years Ended December 31,	
	2025	2024
Modified taxable income	\$ 141,615	\$ 26,492
Tax rate	37%	37%
Federal income tax expense	52,398	9,802
Deferred federal income tax expense (benefit)	53,613	(81,856)
Change in valuation allowance	(106,011)	72,054
Income tax expense (benefit), net	<u>\$ -</u>	<u>\$ -</u>

United Gilsonite Laboratories Asbestos Personal Injury Trust

Notes to Special Purpose Financial Statements December 31, 2025 and 2024

Temporary differences between financial reporting income and taxable income generate deferred tax assets and liabilities, as follows:

	December 31,	
	2025	2024
Net operating loss carryforward	\$ 497,773	\$ 550,171
Unrealized gain on investments	(416,045)	(362,432)
Valuation allowance	(81,728)	(187,739)
Deferred tax liability, net	\$ -	\$ -

At December 31, 2025, the Trust had approximately \$1,345,300 of net operating loss carryforwards with \$488,800 expiring in years 2034 through 2037 and \$856,500 having no expiration date. The future ability of the Trust to benefit from these carryforwards is uncertain; therefore, management has determined that a valuation allowance for the entire deferred tax asset is necessary since it is more likely than not that the benefits will not be fully realized. The amount of income taxes the Trust pays is subject to ongoing audits by federal authorities.

Note 5 - Trust Advisory Committee and Future Claimants' Representative

The Trust Agreement sets forth the role and responsibility of the Trust Advisory Committee ("TAC") and Future Claimants' Representative ("FCR"). The members of the TAC serve in a fiduciary capacity representing all holders of present Asbestos Claims ("Current Claimants"). The Trustee is required to consult with or obtain the consent of the TAC on certain matters identified in the Trust Agreement and the TDP. The TAC is comprised of five attorneys who are engaged by Current Claimants.

The FCR serves in a fiduciary capacity, representing the interests of the individuals who may file an Asbestos Claim in the future, but who at this time are unknown to the Trust ("Future Asbestos Claimants"). His role, in part, is to protect rights of the Future Asbestos Claimants. The Trustee is required to consult with or obtain the consent of the FCR on certain matters identified in the Trust Agreement and the TDP.



Independent Member of Nexia

cohnreznick.com

**UNITED STATES BANKRUPTCY COURT
FOR THE MIDDLE DISTRICT OF PENNSYLVANIA**

IN RE:	)	
	)	Chapter 11
	)	
UNITED GILSONITE	)	Case No. 5:11-bk-02032 (RNO)
LABORATORIES,	)	
A PENNSYLVANIA CORPORATION,¹	)	
	)	
REORGANIZED DEBTOR.	)	

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on April 21, 2026, she caused a copy of the *Annual Report, Financial Statements and Results of Operations of the United Gilsonite Laboratories Asbestos Personal Injury Trust for the Fiscal Year Ended December 31, 2025*, to be served on the parties listed below via email.

/s/ Andrea L. Ducayet

Beth Gori
Gori, Julian & Associates, P.C.
156 North Main Street
Edwardsville, IL 62025
Email: beth@gorijulianlaw.com

Ethan Early
Early, Lucarelli, Sweeney & Meisenkothen
(an Association of Professional LLCs)
The Early Law Firm, LLC
360 Lexington Avenue, 20th floor
New York, NY 10017
Email: early@elslaw.com

Joseph W. Belluck
Belluck & Fox LLP
546 Fifth Avenue, 4th Floor
New York, NY 10036
Email: jbelluck@belluckfox.com

¹ The last four digits of the Debtor's federal tax identification number are 7530.

Jonathan Ruckdeschel
The Ruckdeschel Law Firm, LLC
8357 Main Street
Ellicott City, MD 20143-4603
Email: ruck@rucklawfirm.com

John P. Comerford
Lipsitz & Ponterio, LLC
135 Delaware Avenue, 5th floor
Buffalo, NY 14202
Email: JPC@lipsitzponterio.com

Natalie D. Ramsey
Robinson+Cole
1201 N. Market Street, Suite 1406
Wilmington, DE 19801
Email: nramsey@rc.com

Laurie A. Krepto
Robinson+Cole
1650 Market Street, Suite 3030
Philadelphia, PA 19103
Email: lkrepto@rc.com

James L. Patton
Young Conaway Stargatt & Taylor, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
Email: jpatton@ycst.com

Edwin J. Harron
Young Conaway Stargatt & Taylor, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
Email: eharron@ycst.com